Send by Wall Street Journal (blog)

now-hostile bid from French drug maker Sanofi-Aventis, the WSJ reports. People familiar with the matter tell the paper the Boston biotech isn't actively [...]

Send by PhysiciansMoney

So the rumors were true: French drug giant approached Genzyme about a possible acquisition, sparking rumors the company will attract rival suitors in the U.S. Meanwhile, shares of Onyx Pharmaceuticals and Oncolytics Biotech rose on upbeat reports on clinical trials of their cancer treatments. [...]

Send by willandrews

Pocono Township in Monroe County, Pennsylvania is investing more than $70 million to enhance its sewer system from Sanofi Pasteur in Swiftwater through its piece of Route 611 toward Stroudsburg. [...]

Send by Examiner.com

While the top brass at Sanofi Aventis are making an active bid to acquire Genzyme Corporation, the scientists at the companies are dueling it out at the [...]

Send by TheStreet.com

Genzyme said in a regulatory filing Thursday that Sanofi's CEO dangled the possibility of paying as much as $80 a share for Genzyme at a meeting on Sept. [...]

Send by webmasterfdi

PharmaCom, a pharmacutical distributor is associated with companies like Pfizer, AstraZeneca, GlaxoSmithKline, Eli Lilly and Sanofis Aventisl. We distribute pharmacy products, pharmaceuticals products of anti aging, arthritis, breathing problems, malaria treatment in Europe and to other countries. [...]

Send by peepsbaby1

On March 16, 2010 Senator Kohl requested a response from six major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Lilly, Novartis, Pfizer, and Sanofi-aventis) to answer direct questions about the drug price discrepancies. [...]

Send by FierceBiotech

Sanofi execs are guiding analysts today on its progress with new diabetes and cancer drugs, but most of their guests are likely to be more focused on the [...]

Send by Forbes

Sanofi has made previous attempts at a takeover, which Genzyme rejected. Genzyme noted in its most recent announcement that the current offer is not [...]

Send by ysoylemez

Abott, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Hoffman-La-Roche, Johnson&Johnson, Merck&Co, Novartis, Pfizer, Sanofi Aventis, www.ngpharma.com [...]

Send by seasidesam

Find information regarding pertussis, also known as whooping cough from Sanofi Pasteur. The Sounds of Pertussis website provides information regarding whooping cough vaccination, symptoms and information. [...]

Send by FierceBiotech

When Sanofi CEO Chris Viehbacher outlined his desire to buy Genzyme for $18.5 billion, he cited the biotech's diagnostics business as one particular area [...]

Send by prstock

PROT.OB,OTC:PROT,Proteonomix Inc,Michael Cohen,Kenneth Steiner,Roger Fidler,therapeutics,Proteoderm Inc,anti-aging skin care,StromaCel Inc,cardiovascular disease,NASDAQ:KERX,KERX,Keryx Biopharmaceuticals Inc,Ron Bentsur,cancer,renal disease,Zerenex,perifosine,KRX-0401,NYSE:SNY,SNY,Sanofi-Aventis,healthcare,Scripps Genomic Medicine [...]

Send by FierceBiotech

Some Genzyme investors aren't willing to wait and see if the Big Biotech's board can be gradually lured to the bargaining table by Sanofi's slow motion M&A [...]

Send by Methoxyroxy

Since Chris Viebacher was tapped as CEO of Sanofi-Aventis in September 2008, the company has inked more than $17 billion in deals. Now, with the latest deal rumored to be in the $20 billion range, we're looking back at Viebacher's deal-saturated reign. [...]

Send by robbyyy

Sanofi-aventis and bio-pharmaceutical company CureDM have entered into a global license agreement on Pancreate, a new human peptide which can reportedly restore a patients ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes. [...]

Send by ckscience

As reported on the PharmaTimes Sanofi-Aventis, a global healthcare company, has been in talks with a partner to plan their expansion into the Japanese generics market. [...]

Send by Moneycontrol.com

Deal-starved bankers are falling over themselves to get a slice of Sanofi-Aventis's hostile USD 18.5 billion bid for US biotech company Genzyme, [...]

Send by Benzinga

Deutsche Bank analysts participated in the conference call between Sanofi Aventis (NYSE: SNY) and Genzyme (NASDAQ: GENZ). According to SNY, CEOs of both [...]

Send by Boston Globe

Sanofi said its chief made no such representation. Genzyme said Termeer spoke of the company's intrinsic value. Viehbacher said Termeer wouldn't tell him [...]

Send by Reuters (press release)

O) will be in focus after French drugmaker Sanofi-Aventis (SASY.PA) launched a hostile bid for the biotech firm at $69 per share, or $18.5 billion, [...]

Send by CNNMoney

By CNNMoney.com staffOctober 4, 2010: 4:39 AM ET LONDON (CNNMoney.com) -- French drugmaker Sanofi-Aventis is going hostile with its $18.5 billion takeover [...]

Send by Wall Street Journal

Deal news was grabbing the immediate attention of investors Monday, after French drug maker Sanofi-Aventis (SNY) announced a hostile, $18.5 billion bid for [...]

Send by Moneycontrol.com

Deal-starved bankers are falling over themselves to get a slice of Sanofi-Aventis's hostile USD 18.5 billion bid for US biotech company Genzyme, [...]

Send by canadian52

Rui Song, 14, is seen at the National Research Council. She won 2010 National Sanofi-Aventis BioTalent Challenge Award. A Saskatoon teenager with a passion for studying pathogens has become the youngest person to win the top prize in the 17-year history of a national biotech competition. [...]